Palbociclib
![]() |
- ₹10684.28 - ₹43061.85
- Product name: Palbociclib
- CAS: 571190-30-2
- MF: C24H29N7O2
- MW: 447.53
- EINECS:810-186-2
- MDL Number:MFCD11840850
- Synonyms:PD 0332991;OTAVA-BB 1115529;Palbociclib;OTAVA-BB 1115529/PD0332991;Palbociclib(PD0332991);Palbociclib(free base);PALBOCICLIB PD 0332991;OTAVA-BB 1115529;API-Anti-Tumer;palbociclib (OTAVA-BB 1115529)
2 prices
Selected condition:
Brand
- Sigma-Aldrich(India)
Package
- 5MG
- 25MG
- ManufacturerSigma-Aldrich(India)
- Product numberPZ0383
- Product descriptionPalbociclib ≥98% (HPLC)
- Packaging5MG
- Price₹10684.28
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberPZ0383
- Product descriptionPalbociclib ≥98% (HPLC)
- Packaging25MG
- Price₹43061.85
- Updated2022-06-14
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Sigma-Aldrich(India) | PZ0383 | Palbociclib ≥98% (HPLC) | 5MG | ₹10684.28 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | PZ0383 | Palbociclib ≥98% (HPLC) | 25MG | ₹43061.85 | 2022-06-14 | Buy |
Properties
Melting point :200 ºC
Boiling point :711.5±70.0 °C(Predicted)
Density :1.313±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :Soluble in DMSO (up to 2 mg/ml with warming)
pka :8.66±0.10(Predicted)
form :powder
color :white to beige
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
Boiling point :711.5±70.0 °C(Predicted)
Density :1.313±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :Soluble in DMSO (up to 2 mg/ml with warming)
pka :8.66±0.10(Predicted)
form :powder
color :white to beige
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
Safety Information
Symbol(GHS): |
![]() ![]() |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Palbociclib is a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor approved by the FDA to treat hormone receptor-positive (HR+) human epidural growth factor 2-negative (HER2-) metastatic breast cancer. It is used in combination with letrazole as the first-line hormonal-based therapy in postmenopausal women, or with fulvestrant in women with disease progression following hormonal therapy. Palbociclib was discovered at Warner- Lambert and developed by Pfizer after their merger. Pfizer is also studying the effectiveness of palbociclib in a variety of other cancers at various stages in the clinic.More related product prices
Lenvatinib Dacomitinib (PF299804) 871700-17-3 Cabozantinib Axitinib GZD 824 Doxorubicin hydrochloride Crenolanib AZD-1208 Ilomastat L-4-THIAZOLYLALANINE 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide PF-04929113 IXABEPILONE PD 0332991 HCl 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one 1439-36-7 OTAVA-BB 1207229Related product price
- Dacomitinib (PF299804)
₹5000-14200 - Axitinib
₹12849.28 - Doxorubicin hydrochloride
₹4491-89190